Gelatin in ICU and Sepsis (GENIUS)

  • End date
    Dec 4, 2022
  • participants needed
  • sponsor
    B. Braun Melsungen AG
Updated on 26 January 2022


This prospective, double-blind randomized controlled trial evaluates the differences in terms of efficacy and safety of gelatin based resuscitation as compared to crystalloid based resuscitation in two parallel groups of patients with severe sepsis / septic shock.

Condition Hypovolemia
Treatment Balanced gelatine solution, Balanced electrolyte solution
Clinical Study IdentifierNCT02715466
SponsorB. Braun Melsungen AG
Last Modified on26 January 2022


Yes No Not Sure

Inclusion Criteria

Male or female patients 18 years of age
Women of child bearing potential must test negative on standard pregnancy test (urine or serum)
Patients with body weight 140 kg
Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis
Patients where antibiotic therapy has already been started (prior to randomization)
Patient who are fluid responsive. Fluid responsiveness is defined as increase of > 10% in mean arterial pressure (MAP) after passive leg raising (PLR)
Signed informed consent by patient, legal representative or authorized person or deferred consent

Exclusion Criteria

Administration of HES, dextrane solutions or > 500 ml of Gelatin solutions within the 24 h prior to randomization
Death expected within the next 48 h (moribund patients as defined by ASA class V)
Patients for whom the need of pressure infusions are expected
Patients with confirmed acute SARS-CoV-2 (COVID-19) infection (as available from routine medical records/ patient chart)
Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration)
Patients receiving therapeutic heparin medication due to chronic coagulation disease / anticoagulation medication (i.e. partial thromboplastin time > 60 sec)
Acutely burned patients
Contraindications according to summary of product characteristics of investigational test and reference product
Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note